Esperion Therapeutics (NasdaqGM:ESPR) M&A announcement March 03, 2026 08:00 AM ET Company ParticipantsBen Halladay - CFOBetty Jean Swartz - Chief Business OfficerDan Bloomfield - Chief Medical OfficerJohn Harlow - Chief Commercial OfficerSerge Belanger - Managing Director in BioPharma Equity ResearchSheldon Koenig - President and CEOConference Call ParticipantsDavid Amsellem - Managing Director and Senior Research AnalystDennis Ding - Vice President and Equity Research AnalystJoseph Pantginis - Managing Dir ...

Financial Data and Key Metrics Changes - For the three months ended December 31, 2025, the net loss was $5.3 million or 26 cents per diluted common share, compared to a net loss of $8.9 million or 61 cents per diluted common share in the prior year's quarter [19] - Research and development costs decreased to $1.3 million from $5.7 million in the same period last year, primarily due to the completion of the Phase 2b QUALITY clinical study [17] - General administrative expenses were $4.1 million compared to $5.2 million in the prior quarter, mainly due to a decrease in share-based compensation [17] - Cash, cash equivalents, and restricted cash balance was $33 million as of December 31, 2025, compared to $15.8 million as of September 30, 2025 [19] Business Line Data and Key Metrics Changes - The company is focused on two main drug development programs: enobosarm and sabizabulin, targeting obesity and cardiovascular diseases respectively [3][4] - Enobosarm has shown potential in a Phase 2b clinical trial for obesity, demonstrating selective fat loss while preserving lean mass [6][7] Market Data and Key Metrics Changes - The FDA has provided regulatory clarity for enobosarm in combination with GLP-1 receptor agonists, indicating at least two possible pathways for approval based on weight loss metrics [8][9] Company Strategy and Development Direction - The company aims to develop enobosarm as a next-generation obesity treatment that preserves lean mass and physical function, addressing the limitations of current GLP-1 receptor agonists [4][5] - A planned Phase 2b PLATEAU clinical study will evaluate enobosarm's effects on weight loss and physical function in older patients initiating semaglutide treatment [12][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's cash position to fund operations through the interim analysis of the Phase 2b PLATEAU study [20] - The company is not currently profitable and has experienced negative cash flow from operations, but the recent public offering has bolstered its financial position [19][22] Other Important Information - The company completed a public offering of 1.4 million shares, generating approximately $23.4 million in net proceeds [16] - The company recorded a gain on the sale of the FC2 Female Condom business in the prior year, which is now classified under discontinued operations [17][18] Q&A Session Summary Question: Why not use the oral semaglutide in this study? - Management explained that the injectable form of semaglutide is preferred to minimize differences in outcomes compared to previous studies [24] Question: Did you discuss the stair climb test with the FDA? - Management confirmed discussions with the FDA regarding the stair climb test as a sensitive measure for assessing physical function in the study [26] Question: Are there any pre-specified decision rules for the interim analysis? - It was clarified that there are no futility analysis or sample size re-estimation associated with the interim analysis [32] Question: What degree of weight loss needs to be seen for functional benefit assessment? - Management indicated that greater than 5% weight loss is a clear criterion, but less than 5% could still be acceptable if accompanied by significant functional benefits [34]

澳大利亚悉尼大学、贝尔德研究所及悉尼皇家阿尔弗雷德王子医院科学家首次证实：人类在心脏病发作 后还能再生心肌细胞。这一发现为治疗心血管疾病带来了全新希望。相关论文已发表于最新一期《循环 研究》杂志。 科学界普遍认为，一旦心脏病发作，大量心肌细胞会永久死亡，受损区域将被疤痕组织取代，导致心脏 泵血功能下降，甚至引发心力衰竭。正因如此，心脏一直被视为"不可再生"的器官。 然而，最新研究打破了这一认知。团队发现，尽管心脏在病损后确实会留下瘢痕，但在这些区域周围， 仍有新的心肌细胞悄然生成。这意味着，人类心脏具备一定的自我修复潜力。 不过团队也坦言，目前这种自然再生能力极为有限，远不足以抵消心脏病带来的破坏。他们希望通过药 物或生物手段，激活并增强心脏自身的再生机制，让其在受伤后能更有效地自我恢复。 团队还开发了一种创新技术，可从患者体内安全获取活体心脏组织样本，并在实验室中建立真实可靠的 人类心脏模型。这不仅避免了对动物模型的过度依赖，也让后续药物筛选和机制研究有了更精准的平 台。他们希望利用这一发现，培育出能逆转心力衰竭的新生心肌细胞，真正实现"修复心脏"而非仅 仅"维持生命"。 团队强调，最新研究使用来自真实患者 ...

Core Viewpoint - Monte Rosa Therapeutics experienced a pre-market surge of over 42%, reaching $22.76, following positive mid-stage results from its MRT-8102 Phase I trial, which demonstrated a significant reduction in C-reactive protein levels in cardiovascular and cardiometabolic disease patients [1] Group 1: Clinical Trial Results - The MRT-8102, a targeted molecular glue degrader for treating NLRP3/IL-1/IL-6 driven inflammatory diseases, showed rapid and sustained systemic inflammation reduction in subjects at increased risk for cardiovascular disease (CVD) [1] - After four weeks of treatment with MRT-8102, C-reactive protein (CRP) levels decreased by 85%, with 94% of participants achieving CRP levels below 2 mg/L, a threshold associated with reduced CVD risk [1]

Core Viewpoint - Shenzhen Sinopharm Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein(a) levels, which are independent risk factors for cardiovascular diseases [1][2]. Group 1: Clinical Trial Approval - The company has been granted a Clinical Trial Approval Notice for SAL0137, allowing it to conduct clinical trials for treating elevated lipoprotein(a) levels [1]. - Elevated lipoprotein(a) is linked to various cardiovascular diseases, including coronary heart disease and ischemic stroke, increasing the risk through multiple mechanisms [1]. Group 2: Potential Impact and Development - If SAL0137 is successfully developed and approved, it could provide new treatment options for patients and address unmet clinical needs, enhancing the company's product pipeline in chronic disease management [2]. - The company will conduct clinical trials in accordance with national drug registration regulations, and the timeline from clinical trials to market approval is subject to various uncertainties, which may not have an immediate impact on the company's performance [2].

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0137, aimed at treating elevated lipoprotein (a) levels, which are independent risk factors for various cardiovascular diseases [1] Group 1: Drug Development - The clinical trial approval allows the company to proceed with testing SAL0137 for its efficacy in treating elevated Lp(a) levels [1] - Preclinical studies indicate that SAL0137 has potential in addressing elevated Lp(a), suggesting significant development prospects [1] Group 2: Health Implications - Elevated Lp(a) levels are linked to increased risks of coronary heart disease, ischemic stroke, peripheral vascular disease, coronary artery calcification, and calcific aortic valve stenosis [1] - Lp(a) contributes to cardiovascular disease risk through mechanisms such as promoting atherosclerosis, inflammation, and thrombosis [1]

2025年12月7日，《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》公布，诺华共有2个新 产品及4个新适应症成功纳入2025年版国家医保药品目录，其中包括全球首款PCSK9mRNA干扰类降胆 固醇药物乐可为(英克司兰钠注射液)。 扬子晚报/紫牛新闻记者于丹丹 校对陶善工 乐可为(英克司兰钠注射液)于2023年8月获得国家药品监督管理局批准，作为饮食的辅助疗法，用于成 人原发性高胆固醇血症(杂合子型家族性和非家族性)或混合型血脂异常患者的治疗，包含：在接受最大 耐受剂量的他汀类药物治疗仍无法达到LDL-C目标的患者中，与他汀类药物、或者与他汀类药物及其他 降脂疗法联合用药，以及在他汀类药物不耐受或禁忌使用的患者中，单独用药或与其他降脂疗法联合用 药。 自1987年以来，诺华已有超过100款创新药物及新适应症在中国获批。2017年以来，诺华有40余款药物 被纳入国家医保药品目录。自2022年起，诺华在中国的新药及新适应症开发已实现100%与全球保持同 步。2024年，诺华的创新药物惠及了约8070万中国患者。据悉，诺华将借助后续医保政策支持，推动新 增纳入的创新药转化为患者可及的获益。 心血管疾病 ...

Financial Data and Key Metrics Changes - The company anticipates a greater than $5 billion commercial opportunity starting at the end of the decade and escalating into the early 2030s [10] - The influenza program is expected to provide protection to approximately 110 million people in the U.S., with 85 million being high-risk or immunocompromised individuals [9] Business Line Data and Key Metrics Changes - The launch of Ohtuvayre for COPD treatment has received excellent feedback, and the company sees a significant opportunity to scale this product [17][18] - Winrevair in pulmonary arterial hypertension (PAH) is meeting high expectations, with continuous positive feedback from the medical community [28][29] Market Data and Key Metrics Changes - In the last influenza season, there were 1.6 million hospitalizations due to influenza in the U.S., highlighting the high unmet medical need [10] - The company is seeing strong uptake in the triple segment of the PAH population, with plans to penetrate further into the dual category [32] Company Strategy and Development Direction - The company is focusing on the commercialization of CD388, an antiviral treatment for influenza that is strain agnostic and effective across various populations [6][8] - The strategy includes leveraging existing commercial capabilities to enhance the launch and market penetration of new products like Ohtuvayre and Winrevair [20][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the significant unmet need in the influenza market and the potential for CD388 to address this issue effectively [5][6] - The company is optimistic about the future of its respiratory portfolio and the potential for new products to transform patient outcomes [19][20] Other Important Information - The company is preparing for the launch of an oral PCSK9 inhibitor, which is expected to improve access and adherence for patients needing cholesterol management [40][46] - The company is also exploring multiple indications for its TL1A mechanism, which has shown promise in inflammatory and fibrotic diseases [67][68] Q&A Session Summary Question: Insights on the Cidara deal and its growth opportunity - Management highlighted the high unmet medical need for influenza treatment and the strain-agnostic efficacy of CD388, which is expected to be a significant commercial opportunity [5][6] Question: Commercial approach for high-risk patients - The company plans to include both vaccinated and unvaccinated high-risk individuals in the phase 3 program, with payer research indicating a favorable price point for the treatment [12][13] Question: Feedback on Ohtuvayre and its market potential - The feedback from customers has been excellent, and the company believes it can significantly scale the product using its commercial engine [17][18] Question: Future steps for Winrevair in PAH - Management expressed confidence in the product's performance and noted that they are seeing positive feedback and uptake in the market [28][29] Question: Expectations for the oral PCSK9 program - The company anticipates that the oral PCSK9 will provide robust LDL lowering and improve access for patients, potentially changing treatment guidelines [40][46] Question: Update on Gardasil and vaccine portfolio - The company expects modest growth for Gardasil moving forward, with ongoing efforts to drive vaccination rates globally [54][55] Question: TL1A mechanism and future indications - Management is optimistic about the TL1A mechanism's potential across multiple indications, with several phase 2 studies planned [67][68]

Core Insights - Huadong Medicine's subsidiary, Zhejiang Daer Biotechnology, announced significant results from the Phase II clinical study of the first-in-class long-acting triple agonist DR10624 for treating severe hypertriglyceridemia (SHTG) at the AHA 2025 conference [1][3] Group 1: Product and Clinical Research - DR10624 is a first-in-class long-acting triple-target agonist that uniquely targets FGFR1c/Klothoβ (FGF21R), GLP-1R, and GCGR, designed using the MultipleBody technology platform [2] - The drug intervenes in metabolic regulation by enhancing lipid oxidation, suppressing fat generation, improving insulin sensitivity, promoting fat breakdown, and effectively reducing appetite [2] - The Phase II clinical study results for DR10624 were presented as a groundbreaking report at AHA 2025, marking a significant achievement for Chinese cardiovascular research [3] Group 2: Market Potential and Competitive Landscape - SHTG poses a growing public health burden, with limited effective clinical treatment options currently available, highlighting a significant unmet medical need [3] - Huadong Medicine is preparing for the Phase III clinical study of DR10624, having submitted a clinical trial application to the FDA in September 2025, which was approved in October 2025 [4] - The focus on the FGF21 target presents a high barrier to entry and scarcity in the global market, with few similar drugs in clinical stages, indicating substantial future growth potential [4][5] Group 3: Strategic Positioning - Huadong Medicine's strategic evolution in endocrine therapy has progressed from traditional glucose-lowering drugs to weight management and now to cutting-edge indications like SHTG, enhancing its technological moat [5]

Financial Data and Key Metrics Changes - Revenues increased by 12% year over year to $9.6 billion, driven by strong performance across key growth drivers [12][20] - Non-GAAP operating margin was reported at 47%, reflecting significant investments across the business [12][15] - Free cash flow generated in the third quarter was $4.2 billion, indicating operational momentum [15] Business Line Data and Key Metrics Changes - Repatha sales reached $794 million, up 40% year over year, now annualizing at approximately $3 billion [20] - Evenity delivered $541 million in sales, a 36% increase year over year, with a 44% growth in the U.S. [22] - The rare disease portfolio grew 13% year over year to $1.4 billion, now annualizing at over $5 billion [24] - Oncology portfolio generated $2.3 billion in sales, growing 9% year over year [27] Market Data and Key Metrics Changes - The biosimilar portfolio saw sales increase by 52% year over year to $775 million, now annualizing at $3 billion [28] - Uplizna sales increased 46% year over year to $155 million, with significant uptake among rheumatologists [24] Company Strategy and Development Direction - The company is focused on expanding access to medicines through initiatives like Amgen Now, which offers Repatha at a significantly reduced price [5][22] - Continued investment in manufacturing with over $3 billion planned for the U.S. in 2025, building on over $40 billion since 2017 [7][12] - The company aims to drive innovation in areas of high unmet medical need while maintaining rigorous financial discipline [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining long-term growth, supported by a broad base of innovative medicines [4][11] - The company raised its 2025 guidance for total revenues to a range of $35.8-$36.6 billion and non-GAAP earnings per share between $20.60 and $21.40 [17] - Management highlighted the importance of the Vesalius CV study results for Repatha, which demonstrated significant cardiovascular event reduction [58][60] Other Important Information - The company is actively engaging with policymakers to support policies that improve access and protect innovation [10] - The launch of Uplizna in new indications is anticipated, with a PDUFA date set for December 14, 2025 [33] Q&A Session Summary Question: Confidence in Olpasiran and Business Development Approach - Management remains confident in Olpasiran's potential, citing strong genetic and epidemiological data supporting its efficacy [44] - The return to pre-Horizon debt levels does not significantly impact the company's business development strategy, which remains focused on earlier-stage opportunities [45][46] Question: 2026 Guidance and R&D Expenses - Key growth drivers will influence the top line, with a focus on maintaining industry-leading margins while investing in R&D [50][52] - R&D expenses are expected to stabilize after a significant increase over the past year, with ongoing investments in late-stage programs [51] Question: Vesalius CV Results Impact - The Vesalius CV study is expected to significantly enhance Repatha's market opportunity, with a focus on improving cardiovascular care [58][60] - Management emphasized the importance of the study's findings for primary care physicians and the broader healthcare community [61] Question: New Biosimilar Guidance Impact - The new FDA biosimilar guidance does not change the company's strategic focus on biosimilars, which continue to be a strong growth area [65] - The company is well-positioned to adapt to any new regulatory requirements while maintaining competitiveness in the biosimilar market [66][67]